A $43 billion deal that doubles the pharma giant’s cancer pipeline shows that M&A is back on the table in pharma.
A $43 billion deal that doubles the pharma giant’s cancer pipeline shows that M&A is back on the table in pharma.
Copyright © 2024 | WordPress Theme by MH Themes